G Iii Apparel Group Ltd /De/
$776.29M- Market cap
- $1.17B
- Debt
- +$11.74M
- Cash
- −$406.66M
Capital structure 99% equity / 1% debt · EV / Revenue 0.26x · EV / EBITDA 5.43x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GIII stock price at discount vs CTXR $27.76 current versus $12.59K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Implied fair value · at GIII's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GIII FY 2026 (ended Jan 31, 2026) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 0.26x · EV / EBITDA 5.43x
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
GIII carries the larger enterprise value at $776.29M against -$31.66M; CTXR trades on the lower EV / EBITDA multiple (0.96x vs 5.43x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
G III APPAREL GROUP LTD /DE/ · implied price per share
Bear
$81.16
Base
$93.91
Bull
$110.53
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.01x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
-2.76x
1.45x
Cash and equivalents
Liquid reserves on the balance sheet
$406.66M
$41.71M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LEVI STRAUSS & CO
GIII vs LEVI
Capri Holdings Ltd
GIII vs CPRI
TAPESTRY, INC.
GIII vs TPR
AMERICAN EAGLE OUTFITTERS INC
GIII vs AEO
Zomedica Corp.
GIII vs ZOM
Aquestive Therapeutics, Inc.
GIII vs AQST
ACADIA PHARMACEUTICALS INC
GIII vs ACAD
AMGEN INC
GIII vs AMGN
GILEAD SCIENCES, INC.
GIII vs GILD
AbbVie Inc.
GIII vs ABBV
$11.74M
-$6.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.